About 373 results
Open links in new tab
  1. Extended-spectrum beta-lactamases - UpToDate

    Mar 8, 2024 · The types and detection of extended-spectrum beta-lactamases as well as the epidemiology and treatment of organisms that produce them are discussed in this topic. The …

  2. 超广谱β-内酰胺酶 - UpToDate

    Mar 8, 2024 · 本专题将讨论ESBL的类型和检测,以及产ESBL病原体的流行病学和治疗。 产ESBL病原体常致感染的临床特征和诊断详见其他专题。

  3. Clinical features, diagnosis, and treatment of Klebsiella …

    Comprehensive insights into Klebsiella pneumoniae infection, covering clinical features, diagnosis, and treatment strategies for healthcare professionals.

  4. Extended-spectrum beta-lactamases - UpToDate

    Oct 10, 2022 · Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infect 2005; 51:211.

  5. Sputum cultures for the evaluation of bacterial pneumonia

    Jul 28, 2025 · This webpage provides information on sputum cultures for evaluating bacterial pneumonia, including diagnostic methods, interpretation, and clinical implications.

  6. Catheter-associated urinary tract infection in adults - UpToDate

    Nov 22, 2024 · INTRODUCTION Urinary catheters are placed for several reasons, including diagnostic and therapeutic needs. The presence of a catheter increases the risk of bacteriuria, …

  7. Overview of antibacterial susceptibility testing - UpToDate

    Apr 10, 2025 · Antibacterial susceptibility testing helps determine the effectiveness of antibiotics against specific bacteria, aiding in effective treatment decisions.

  8. Gram-negative bacillary bacteremia in adults - UpToDate

    May 1, 2025 · Gram-negative bacillary bacteremia is a frequent cause of sepsis, often managed before microbiological data is received.

  9. UpToDate

    Aug 8, 2024 · UpToDate ... UpToDate

  10. Daptomycin: An overview - UpToDate

    Aug 5, 2024 · Daptomycin is a lipopeptide antimicrobial effective against gram-positive organisms, including resistant pathogens like MRSA and VRE.